Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.
| Website: | www.galectintherapeutics.com |
| Email: | ir@galectintherapeutics.com |
| Main Phone: | +1 678 620-3186 |
| Address: | 4960 Peachtree Industrial Boulevard |
| Address 2: | Suite 240 |
| State: | GA |
| City / Town: | Norcross |
| Country: | USA |
| Postal Code: | 30071 |
| Exchange: | NSC |
| CEO: | Harold H. Shlevin |
| Employees: | 6 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
For the second week in a row, the LD Micro Index led the pack, picking up over 1%, while the DJIA trailed dropping 49 bps.
Last day of the Roth conference. 30 biotech companies presenting including GALT, EPIX, CLRB. Learn more about what is happening in Dana Point and what you should be watching from Equities Research
We looked at Galectin Therapeutics and are trying to determine what needs to happen for shares to become a darling stock in 2017 and gain some upside momentum. We are in touch with the company to determine what the future holds
Galectin is strategically positioned to treat diseases with unmet medical needs. GR-MD-02 has shown positive results treating psoriasis, lung fibrosis, kidney fibrosis, and heart and vascular fibrosis.
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where
The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will
Everyone has an opinion on the markets. These days it seems to be fairly evenly split between the pundits calling for a correction. The bullish ones saying there is nowhere else to invest, and the
To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and
Intercept Pharmaceuticals (ICPT) continued its wild, roller-coaster ride on Tuesday, with a second-straight day of major losses. Intercept made news last week after its treatment for fatty liver
Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.
| Website: | www.galectintherapeutics.com |
| Email: | ir@galectintherapeutics.com |
| Main Phone: | +1 678 620-3186 |
| Address: | 4960 Peachtree Industrial Boulevard |
| Address 2: | Suite 240 |
| State: | GA |
| City / Town: | Norcross |
| Country: | USA |
| Postal Code: | 30071 |
| Exchange: | NSC |
| CEO: | Harold H. Shlevin |
| Employees: | 6 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
For the second week in a row, the LD Micro Index led the pack, picking up over 1%, while the DJIA trailed dropping 49 bps.
Last day of the Roth conference. 30 biotech companies presenting including GALT, EPIX, CLRB. Learn more about what is happening in Dana Point and what you should be watching from Equities Research
We looked at Galectin Therapeutics and are trying to determine what needs to happen for shares to become a darling stock in 2017 and gain some upside momentum. We are in touch with the company to determine what the future holds
Galectin is strategically positioned to treat diseases with unmet medical needs. GR-MD-02 has shown positive results treating psoriasis, lung fibrosis, kidney fibrosis, and heart and vascular fibrosis.
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where
The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will
Everyone has an opinion on the markets. These days it seems to be fairly evenly split between the pundits calling for a correction. The bullish ones saying there is nowhere else to invest, and the
To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and
Intercept Pharmaceuticals (ICPT) continued its wild, roller-coaster ride on Tuesday, with a second-straight day of major losses. Intercept made news last week after its treatment for fatty liver
| Last Price 2.90 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid 2.85 | Bid Size 100.00 | Ask 3.05 | Ask Size 100.00 |
| Open N/A | High N/A | Low N/A | Prev Close 2.90 |
| Last Trade | Volume 0 | 52 Wk Hi 6.06 | 52 Wk Low 2.83 |
| Market Cap 165 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 56,886,059.00 | EPS (TTM) -0.39 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 48 | 56 |
| Number of Buys | 21 | 27 |
| Number of Sells | 27 | 29 |
| Net Activity | -532054 | -661893 |
| Last 10 Buys | Shares |
|---|---|
| Kevin D. Freeman | 1,000 |
| Kevin D. Freeman | 1,000 |
| Marc Rubin | 1,000 |
| Kevin D. Freeman | 1,000 |
| Kevin D. Freeman | 1,000 |
| Theodore H. Zucconi | 1,000 |
| Arthur R. Greenberg | 1,000 |
| Peter G. Traber | 1,000 |
| Kevin D. Freeman | 1,000 |
| Peter G. Traber | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Harold H. Shlevin | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| James C. Czirr | 1,000 |
| Jack W. Callicutt | 1,000 |
| Harold H. Shlevin | 1,000 |
| Jack W. Callicutt | 1,000 |
| Harold H. Shlevin | 1,000 |
| Jack W. Callicutt | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 12 | 12 | 12 | 12 |
| Low Target Price Estimate | 5 | 5 | 5 | 5 |
| Mean Target Price Estimate | 8.33 | 8.33 | 8.33 | 8.33 |
| Standard Deviation | 3.51 | 3.51 | 3.51 | 3.51 |
| Date of Most Recent Estimate | 05/31/18 | 05/31/18 | 05/15/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait